IDYA

Business Context and Reporting Period

Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: IDEAYA is a clinical-stage precision medicine oncology company focused on discovering and developing transformative therapies for cancer, specifically targeting synthetic lethality and antibody-drug conjugates (ADCs). The company has no products approved for commercial sale and has incurred significant losses since inception.

Key Financial Metrics

Note: Revenue in 2025 was driven primarily by a $210.0 million upfront payment from a new license agreement with Servier. The company reported no product sales revenue.

Material Changes vs. Prior Period

• Revenue Surge: Collaboration revenue increased by 3,024% to $218.7 million, primarily due to the recognition of revenue from the Servier License Agreement executed in August 2025. In contrast, 2024 revenue was $7.0 million, derived from a milestone payment under the GSK Collaboration Agreement.
• Reduced Net Loss: Net loss improved significantly from $274.5 million in 2024 to $113.7 million in 2025, largely offset by the Servier revenue recognition.
• Expense Growth: Operating expenses increased by 13% to $378.0 million. General and Administrative expenses rose 61% due to increased personnel costs and legal/consulting fees. R&D expenses increased 7%, driven by clinical trial advancements, partially offset by a $75.0 million upfront payment made to Hengrui Pharma in 2024.
• Collaboration Shifts: The company terminated its Collaboration, Option and License Agreement with GSK (effective March 9, 2026), regaining control of the IDE705 and IDE275 programs. Conversely, it entered a major exclusive license with Servier for darovasertib outside the U.S.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($1.05 billion) are sufficient to fund planned operations for at least 12 months from the filing date.
• Clinical Milestones:
  • Darovasertib (Uveal Melanoma): Topline data from the Phase 2/3 OptimUM-02 trial is expected in Q1 2026. A Phase 3 neoadjuvant trial (OptimUM-10) is ongoing, and a Phase 3 adjuvant trial (OptimUM-11) is planned for initiation in H1 2026.
  • ADC/DDR Combinations: IDE849 (DLL3 ADC) and IDE161 (PARG inhibitor) combination trials are targeted for initiation in Q2 2026. IDE034 (B7H3/PTK7 ADC) expects first patient in Q1 2026.
  • MTAP Pathway: IDE397 (MAT2A inhibitor) data updates are targeted for 2026. IDE892 (PRMT5 inhibitor) Phase 1 is expected to begin in Q1 2026.

Risks and Contingencies

• Dependence on Partners: Commercial success of darovasertib outside the U.S. depends on Servier's performance. The company relies on third-party manufacturers (CMOs) and research organizations (CROs) for all clinical and commercial production.
• Regulatory Uncertainty: No products are approved. Success depends on clinical trial outcomes and FDA/regulatory approvals, which are uncertain and costly.
• Capital Requirements: The company expects to continue incurring significant losses and will require additional capital to fund operations and development. Future financing may result in dilution.
• Intellectual Property: The company relies on in-licensed IP (e.g., from Novartis, Hengrui, Biocytogen) and faces risks regarding patent validity, enforcement, and potential infringement claims.

Key Facts for Investor Verification

• Servier Deal Terms: Verify the specific milestones and royalty rates (mid-teens to low-twenties) associated with the $210 million upfront payment and potential $320 million in future milestones.
• GSK Termination Impact: Confirm the financial and operational implications of the GSK agreement termination and the transition of IDE705 and IDE275 programs back to IDEAYA.
• Cash Burn Rate: Assess the sustainability of the $1.05 billion cash position against the projected increase in R&D and G&A expenses as multiple Phase 3 trials commence.
• Darovasertib Trial Data: Monitor the Q1 2026 topline data release for the OptimUM-02 trial, which is critical for potential accelerated FDA approval.
• Manufacturing Dependencies: Review the specific agreements with CMOs, particularly regarding the BIOSECURE Act risks mentioned in the filing regarding foreign suppliers.